Total Payments
$695,317
2024 Payments
$42,235
Companies
72
Transactions
1,985
Medicare Patients
6,745
Medicare Billing
$2.5M
Payment Breakdown by Category
Other$439,313 (63.2%)
Consulting$135,531 (19.5%)
Travel$86,400 (12.4%)
Food & Beverage$33,682 (4.8%)
Education$390.90 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $432,868 | 164 | 62.3% |
| Consulting Fee | $135,531 | 63 | 19.5% |
| Travel and Lodging | $86,400 | 405 | 12.4% |
| Food and Beverage | $33,682 | 1,329 | 4.8% |
| Honoraria | $6,445 | 4 | 0.9% |
| Education | $390.90 | 20 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $324,829 | 560 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $101,735 | 110 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $69,633 | 69 | $0 (2024) |
| GENZYME CORPORATION | $43,225 | 64 | $0 (2024) |
| PFIZER INC. | $21,172 | 96 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $19,442 | 68 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $19,414 | 18 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $12,084 | 137 | $0 (2024) |
| Celgene Corporation | $8,216 | 60 | $0 (2024) |
| Seagen Inc. | $7,169 | 21 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $42,235 | 194 | Regeneron Healthcare Solutions, Inc. ($20,474) |
| 2023 | $77,995 | 240 | Lilly USA, LLC ($45,348) |
| 2022 | $123,373 | 301 | Regeneron Healthcare Solutions, Inc. ($53,615) |
| 2021 | $59,515 | 183 | Lilly USA, LLC ($21,970) |
| 2020 | $24,549 | 114 | Lilly USA, LLC ($16,647) |
| 2019 | $146,323 | 346 | Lilly USA, LLC ($101,632) |
| 2018 | $176,063 | 429 | Lilly USA, LLC ($96,812) |
| 2017 | $45,265 | 178 | Millennium Pharmaceuticals, Inc. ($19,414) |
All Payment Transactions
1,985 individual payment records from CMS Open Payments — Page 1 of 80
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $25.33 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $26.52 | General |
| 12/17/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $26.39 | General |
| Category: Oncology | ||||||
| 12/16/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.07 | General |
| 12/09/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.65 | General |
| Category: Hematology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $31.92 | General |
| Category: Oncology | ||||||
| 12/05/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $30.91 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: Oncology | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $32.34 | General |
| Category: Oncology | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $32.40 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.16 | General |
| Category: Hematology | ||||||
| 11/26/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.37 | General |
| 11/22/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $31.34 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: Oncology | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.57 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $6.81 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $25.73 | General |
| Category: HORMONE THERAPY | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: Immunology | ||||||
| 11/07/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $15.14 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $30.63 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 1,553 | 120,114 | $1.9M | $792,665 |
| 2022 | 43 | 1,818 | 111,962 | $2.2M | $799,083 |
| 2021 | 35 | 1,609 | 32,759 | $1.1M | $414,701 |
| 2020 | 38 | 1,765 | 82,890 | $1.5M | $541,721 |
Total Patients
6,745
Total Services
347,725
Medicare Billing
$2.5M
Procedure Codes
156
All Medicare Procedures & Services
156 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 9,800 | $784,000 | $421,915 | 53.8% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 66 | 73 | $222,796 | $81,186 | 36.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 14 | 16,360 | $163,600 | $38,757 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 177 | 399 | $72,618 | $34,960 | 48.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 69 | 295 | $74,340 | $28,846 | 38.8% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 20 | 31,500 | $94,500 | $27,539 | 29.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 1,500 | $45,000 | $27,462 | 61.0% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 77 | 85 | $80,835 | $23,514 | 29.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 200 | 331 | $41,375 | $20,431 | 49.4% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 11 | 12 | $36,624 | $12,429 | 33.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 63 | 70 | $28,000 | $11,602 | 41.4% |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 2023 | 14 | 36,840 | $73,680 | $9,491 | 12.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 51 | 246 | $14,760 | $5,453 | 36.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 25 | 108 | $13,500 | $5,266 | 39.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $9,100 | $4,246 | 46.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 38 | 68 | $9,656 | $4,154 | 43.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 31 | 31 | $10,633 | $4,152 | 39.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $8,960 | $3,637 | 40.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 36 | 72 | $8,568 | $3,364 | 39.3% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 70 | 76 | $28,652 | $3,358 | 11.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 57 | 284 | $22,152 | $2,992 | 13.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 12 | 47 | $5,922 | $2,558 | 43.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 16 | $3,920 | $2,208 | 56.3% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 35 | 43 | $13,717 | $2,188 | 16.0% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2023 | 20 | 23 | $7,728 | $1,806 | 23.4% |
About Dr. Roopesh Kantala, M.D
Dr. Roopesh Kantala, M.D is a Medical Oncology healthcare provider based in Mesa, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811922198.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roopesh Kantala, M.D has received a total of $695,317 in payments from pharmaceutical and medical device companies, with $42,235 received in 2024. These payments were reported across 1,985 transactions from 72 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($432,868).
As a Medicare-enrolled provider, Kantala has provided services to 6,745 Medicare beneficiaries, totaling 347,725 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 156 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Mesa, AZ
- Active Since 07/12/2006
- Last Updated 09/17/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1811922198
Products in Payments
- VERZENIO (Drug) $294,316
- LIBTAYO (Biological) $139,611
- ICLUSIG (Drug) $81,251
- Revlimid (Drug) $7,413
- MONOFERRIC (Drug) $6,604
- XALKORI (Drug) $6,543
- IMFINZI (Biological) $5,865
- IBRANCE (Drug) $5,661
- JEVTANA (Drug) $4,882
- GILOTRIF (Drug) $4,734
- ADCETRIS (Biological) $4,365
- Enzalutamide (Drug) $4,263
- LORBRENA (Drug) $4,048
- ZEJULA (Drug) $3,944
- CALQUENCE (Drug) $3,876
- RUBRACA (Drug) $3,804
- IMBRUVICA (Drug) $3,527
- EMPLICITI (Biological) $3,486
- Non-Covered $2,775
- XPOVIO (Drug) $2,313
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.